Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies

被引:2
|
作者
Kim, Inho
Yoon, Sung Soo
Lee, Kyung-Hun
Keam, Bhumsuk
Kim, Tae Min
Kim, Jin-Soo
Kim, Hoon-Gu
Oh, Myoung-Don
Han, Kyou-Sup
Park, Myoung Hee
Park, Seonyang
Kim, Byoung Kook
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul 110744, South Korea
关键词
allogeneic stem cell transplantation; hematological malignancy; reduced intensity conditioning; youths;
D O I
10.1111/j.1399-0012.2006.00512.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
We have conducted a direct comparison of the outcomes of reduced intensity and myeloablative conditioning in younger adults with hematological malignancies < 50 yr. One hundred and five patients received transplants from human leukocyte antigen (HLA)-matched donors, via either reduced intensity (n = 35) or myeloablative conditioning (n = 70). The median ages of the reduced intensity and myeloablative groups were 36 and 33 yr (p = 0.014). Neutrophil engraftment (i.e. time to absolute neutrophil count > 0.5 x 10(9)/L) occurred more rapidly in the reduced intensity group (median: 10 d; range: 0-21 d) than in the myeloablative group (median: 18 d; range: 11-38 d; p < 0.0001). The incidence of grades 2-4 acute graft-vs.-host disease were similar between the reduced intensity and myeloablative groups, at 17% vs. 24% respectively (p = 0.40). The cumulative incidence of day 100 non-relapse mortality was 18% in the reduced intensity group, and 21% in the myeloablative group (p = 0.88). The overall two-yr survival rates were 43% in the reduced intensity group, and 35% in the myeloablative group (p = 0.72). In conclusion, reduced intensity transplantation yielded outcomes comparable with those of myeloablative transplantation in patients under 50 with hematological malignancies.
引用
收藏
页码:496 / 503
页数:8
相关论文
共 50 条
  • [21] Clinicopathologic Characteristics Of Secondary Malignancies In Survivors Of Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Hematologic Malignancies
    Chaulagain, Chakra P.
    Kaul, Esha
    Pilichowska, Monika
    Klein, Andreas K.
    Sprague, Kellie
    Miller, Kenneth B.
    BLOOD, 2013, 122 (21)
  • [22] REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN ACHIEVE BOTH DISEASE CONTROL AND VERY GOOD OUTCOMES IN ELDERLY (&gt;60) PATIENTS WITH HEMATOLOGIC MALIGNANCIES
    Meyers, G.
    Subbiah, N.
    Palmbach, G.
    Kovacsovics, T.
    Abar, F.
    Hayes-Lattin, B.
    Gajewski, J.
    Dunn, A.
    Jacoby, C.
    Slater, S.
    Allen, B.
    Maziarz, R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S284 - S284
  • [23] Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients
    Ditschkowski, M
    Elmaagacli, AH
    Trenschel, R
    Steckel, NK
    Koldehoff, M
    Beelen, DW
    CLINICAL TRANSPLANTATION, 2006, 20 (01) : 127 - 131
  • [24] A PROSPECTIVE COMPARISON OF OUTCOMES AND RESOURCE UTILIZATION IN PATIENTS WITH MYELOID MALIGNANCIES UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) USING MYELOABLATIVE OR REDUCED INTENSITY CONDITIONING
    Gupta, V
    Panzarella, T.
    Li, L.
    Khan, J.
    Alibhai, S.
    Galal, A.
    Kuruvilla, J.
    Lipton, J.
    Messner, H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S270 - S270
  • [25] Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can
    Hamadani, Mehdi
    Devine, Steven M.
    BLOOD, 2009, 114 (12) : 2564 - 2566
  • [26] In vivo T cell depleted unrelated allogeneic stem cell transplantation with a reduced intensity regimen in patients with advanced hematologic malignancies
    Magalhaes-Silverman, M
    Carter, T
    Gingrich, R
    Hohl, R
    Schlueter, A
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 22 - 23
  • [27] Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies
    Petrovic, Aleksandra
    Hale, Gregory
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (04) : 515 - 527
  • [28] Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
    J Mehta
    L I Gordon
    M S Tallman
    J N Winter
    A O Evens
    O Frankfurt
    S F Williams
    D Grinblatt
    L Kaminer
    R Meagher
    S Singhal
    Bone Marrow Transplantation, 2006, 38 : 95 - 100
  • [29] Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
    Mehta, J.
    Gordon, L. I.
    Tallman, M. S.
    Winter, J. N.
    Evens, A. O.
    Frankfurt, O.
    Williams, S. F.
    Grinblatt, D.
    Kaminer, L.
    Meagher, R.
    Singhal, S.
    BONE MARROW TRANSPLANTATION, 2006, 38 (02) : 95 - 100
  • [30] Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
    Le, Robert Quan
    Bevans, Margaret
    Savani, Bipin N.
    Mitchell, Sandra A.
    Stringaris, Kate
    Koklanaris, Eleftheria
    Barrett, A. John
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) : 1162 - 1170